A founder I worked with was building a care gap management platform for underserved communities. Solid idea, real clinical need. He had identified FQHCs as his primary buyer. It made intuitive sense: FQHCs serve exactly the population the product was designed for, clinical staff understood the problem immediately, and feedback from early pilots was genuinely positive. People wanted to use it.
But the deals never closed.
Not because the product failed. Because FQHCs didn’t have the budget to buy it. They operate on thin margins, largely dependent on federal grants and UDS performance incentives. Even when the clinical champion was enthusiastic, there was no discretionary budget line the product could attach to. “We’d love to use this” kept becoming “check back after our next grant cycle.”
After enough of those conversations, we had to ask a harder question: who actually has the financial incentive and the budget to close care gaps at scale in underserved populations?
The answer was payers. Medicaid managed care plans with HEDIS measure performance tied directly to their contract renewals and reimbursement rates. Closing care gaps wasn’t just clinically meaningful for them. It was measurable, reportable, and financially consequential.
The product hadn’t changed. The population it served hadn’t changed. But the buyer, the value framing, and the entire go-to-market had to be rebuilt. That’s not a sales problem. That’s a PMF problem that a successful pilot had quietly masked for over a year.
The Misbelief: “Our Pilot Went Well, So We Have PMF”
Pilots in healthcare are structurally designed to produce positive signals. You have a motivated champion, a forgiving data setup, manual workarounds that won’t survive at scale, and evaluation criteria that nobody fully locked down upfront. When the pilot goes well, it tells you the product can work under favorable conditions. It doesn’t tell you whether the organization can actually buy it, integrate it, or sustain it operationally.
This is the most common place I see founders get stuck. They have real clinical validation. They have user enthusiasm. They have a case study. What they don’t have is a repeatable, scalable path to a signed contract, and they often don’t realize that until the pipeline has been “almost there” for six months.
If you only remember one thing: a successful pilot is permission to find out whether PMF exists. It is not PMF itself.
What Healthcare PMF Actually Requires
Consumer and SaaS PMF share a common structure: people use it, they come back, they tell others, revenue follows. That model assumes the person who gets value is also the person who pays, decides, and integrates. In healthcare, those are almost never the same person.
Healthcare PMF has at least five layers that need to align before the market pulls you forward.
Workflow fit. Does the product fit into how care is actually delivered today, not how it ideally should be? Clinicians and care teams are already stretched. A product that requires meaningful behavior change before it delivers value will be piloted and quietly set aside. Workflow fit means landing inside an existing motion, not beside it.
Stakeholder alignment. In most healthcare sales, the person who uses the product, the person who approves the budget, the person who clears IT and compliance, and the person who sponsors the initiative are four different people with different definitions of success. Enthusiasm from one layer means nothing if another layer quietly kills the renewal.
Red flag: If your strongest internal advocate can’t answer “what budget does this come out of,” you don’t have a buyer. You have a fan.
Reimbursement and incentive logic. Healthcare organizations don’t buy things because they’re clinically good. They buy things connected to how they get paid, how they avoid penalties, or how they reduce measurable cost. The FQHC-to-payer pivot above is a clean example: same product, same clinical problem, completely different financial conversation depending on who’s sitting across the table. FQHCs cared about care gaps but couldn’t monetize closing them faster. Medicaid plans had Star ratings and contract renewal pressure riding on exactly that outcome.
Decision rule: Before finalizing your ICP, map your product’s value to a specific payer incentive, quality measure, cost center, or regulatory requirement your buyer is already being held to. If you can’t make that map precisely, you don’t yet understand your buyer well enough to sell to them.
Integration feasibility. Most health-tech products need data they don’t own: clinical records, claims history, ADT feeds, scheduling data. Getting that data reliably, in a compliant way, at production scale is almost always harder and more expensive than a pilot reveals. A pilot running on manually exported spreadsheets or a one-off HL7 connection is not evidence of integration readiness. It is a deferred problem with a future price tag.
Trust and compliance readiness. Healthcare buyers carry institutional risk with every vendor they onboard. A data breach, a HIPAA gap, or an unvalidated clinical output can mean regulatory exposure or patient harm liability. Their procurement processes and security reviews are not bureaucratic friction. They are rational caution. Founders who treat compliance readiness as something to figure out post-pilot tend to lose deals quietly, without ever being told why.
Where Founders Consistently Fall Short
Most of these mistakes don’t happen because founders are careless. They happen because early healthcare signals are genuinely encouraging, and the structural problems don’t surface until much later.
Anchoring to the wrong buyer early is probably the most expensive mistake. Selling workflow tools to clinicians when the real buyer is a VP of Operations. Building for hospital systems when the contract will actually come from a regional health plan. The product can be entirely right and the buyer assumption completely wrong. Fixing this after you’ve built your GTM around the wrong stakeholder is painful and slow.
Underestimating implementation burden is the other one that catches founders off guard. Enterprise healthcare buyers think about implementation as operational risk, not just onboarding. Every integration, every workflow change, every new screen a staff member has to learn is a cost the buyer is internalizing. Your license fee is not the total cost of adopting you, and sophisticated buyers price that in even when they don’t say it out loud.
Skipping the reimbursement homework is common among founders who come from a product or engineering background. Building something that improves a workflow nobody is being measured on or reimbursed for is not impossible to sell, but it’s significantly harder than it needs to be. The founders who navigate this well do the incentive mapping early, before the product is fully built, not after the pipeline stalls.
A Practical PMF Checklist for Healthcare
Use this before concluding you have PMF, or before raising a round on the back of pilot results.
- Can you name the specific role with budget authority for your product, and have you had a direct conversation with them?
- Can you map your product’s value to at least one quality measure, cost center, reimbursement incentive, or regulatory requirement your buyer is currently held to?
- Do you know what data your product needs at scale, where it lives, and what the realistic integration path looks like beyond your current pilot?
- Has a real IT or security review happened, or have you only spoken to clinical and operational stakeholders?
- Do you have BAA templates ready and at least a basic security posture documented?
- Did your pilot run on production data flows, or on manually prepared exports that won’t survive at scale?
- Have you aligned with your champion on what a successful pilot converts to, including who signs and when?
- Can your product be operationalized by the buyer’s existing staff, or does it require capabilities they don’t currently have?
Closing
Healthcare is one of the few markets where you can have a genuinely useful product, real user enthusiasm, and a successful pilot, and still be years away from PMF. That’s not a flaw in the market. It’s the structure of it.
The buyers carry real institutional risk. The workflows are load-bearing. The data is fragmented and governed carefully for good reason. The incentives are set by payers and regulators, not by user preference. Founders who internalize this early stop chasing validation from the wrong stakeholders and start building toward the conditions that actually produce a repeatable, scalable sale.
PMF in healthcare means a buyer who can pay, will pay, and can absorb your product without breaking their operations in the process. Everything before that is signal. Useful signal, worth acting on, but signal.
